Safety Study of Conventional Versus Micropulse Transscleral Cyclophotocoagulation in Treating End-Stage Glaucoma

A Comparison of the Safety and Efficacy of Conventional Versus Micropulse Transscleral Diode Laser Cyclophotocoagulation in Refractory Glaucoma

Status

UNKNOWN

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00349414

Enrollment

Registered

2006-07-07

Start date

2006-07-31

Completion date

2008-12-31

Last updated

2008-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Glaucoma, Refractory Glaucoma

Keywords

Advanced glaucoma, Refractory glaucoma, Cyclophotocoagulation, Transscleral cyclophotocoagulation, Micropulse transscleral cyclophotocoagulation

Brief summary

The aim of this study is to compare the safety and efficacy of conventional and micropulse transscleral diode laser in the treatment of end-stage glaucoma.

Detailed description

End-stage glaucoma is difficult to treat, and it may sometimes be unresponsive to surgery or medications. A common treatment is the conventional transscleral cyclophotocoagulaion, but it has various side effects. This study specifically aims to compare the intraocular pressure (IOP) lowering effects and the incidence of complications such as hypotony, phthisis, sympathetic ophthalmia, surface conjunctival burns, bulbar conjunctival swelling, decompensation of corneal grafts, hyphema and vitreous hemorrhage, in conventional and the newer micropulse transscleral cyclophotocoagulation.The hypothesis is that the micropulse transscleral cyclophotocoagulation will be as good or better than the conventional transscleral cyclophotocoagulation, with less complications.

Interventions

PROCEDUREMicropulse Transscleral Cyclophotocoagulation

PROCEDUREConventional Transscleral Cyclophotocoagulation

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

22 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* · More than 21 years old * Advanced glaucoma refractory to maximum tolerated medical and surgical treatment * Visual acuity worse than 6/60 * Poor candidates for additional filtration surgery

Exclusion criteria

* · Any eye surgery done within 2 months of enrolment * Any ocular infection or inflammation * Unable to give informed consent

Design outcomes

Primary

Measure	Time frame
Number of patients in each group that had a 30% decrease of IOP from baseline after 6 months	—

Secondary

Measure	Time frame
Number of patients with complications, such as hypotony, phthisis, sympathetic ophthalmia, surface conjunctival burns, bulbar conjunctival swelling, decompensation of corneal grafts, hyphema and vitreous hemorrhage	—

Countries

Singapore

Contacts

Primary ContactAnna Tan, MMed

amwttan@yahoo.com6772-5317

Backup ContactGrace Dizon, MD

gengmd@yahoo.com6772-5317

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026